RWE Study Utilizing the Cala Trio Device in Patients With Essential Tremor

The study objective is to evaluate hand tremor relief in the treated hand following stimulation with the Cala Trio Device in adults with essential tremor, and healthcare resource utilization and total healthcare costs over a 12-month period.

This is a prospective, randomized, dual arm, pragmatic trial in a real-world setting to evaluate the effectiveness and health economics outcomes of the Cala Trio device in reducing hand tremor and improving quality of life as measured by the Bain and Findley Activities of Daily Living (ADL) score relevant to the stimulated upper limb. Healthcare resources utilization and total all-cause healthcare will also be evaluated. The study will recruit approximately 300 patients: 150 in the intervention arm (Cala Trio device)and 150 patients in the standard of care (SOC) arm. Subjects will be randomized to either the intervention arm or the standard of care arm (1:1).Subjects in the SOC arm will be asked to measure their tremor severity by doing daily postural holds with the Cala Trio device without actual stimulation. Subjects in the intervention arm will wear the device at home for a period of 12 months, during which they will deliver 40 min stimulation sessions, which can be started and stopped on demand. After the first month, the subjects who were randomized to the SOC arm will cross over to the intervention arm.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥22years
* Aetna commercial fully insured OR Medicare Advantage population (inclusion of Medicare is contingent upon additional internal approvals)
* Two ICD claims for ET, at least seven days apart, in the last three years OR one ICD claim for ET followed by at least one dispensed pharmaceutical treatment for ET
* Contraindication to standard pharmacological therapy (Asthma, COPD, 1stor 2nddegree heart block) OR indicator of poor pharmacological acceptability as evidenced by drug switching behaviors OR indicator of drug resistance as evidenced by the use of third-line drug therapies including Clozapine, Mirtazapine, Gabapentin, Topiramate, Clonazepam or Alprazolam
* Willing and able to provide informed consent to participate in the study
* Willing and able to follow study protocol requirements
* Patients with PCP or neurologist provider encounter in past 18months

Exclusion Criteria:

* ICD-10 evidence of a pacemaker or defibrillator or a procedure code indicating pacemaker implantation, electrode renewal or calibration
* ICD-10 evidence of a deep brain stimulator or a procedure code indicating DBS implantation
* CPT/HCPCS evidence of thalamotomy, gamma-knife radio surgical thalamotomy
* NDC and CPT evidence of botulinum toxin the last 6 months as therapeutic injection in the upper limb
* Pregnant during the enrollment period
* Evidence of Parkinson's Disease
* Evidence of epilepsy
* Formal diagnosis of hypothyroidism and treatment
* Formal diagnosis of hyperthyroidism without evidence of treatment
* Formal diagnosis of dementia
* Evidence of Treatment with thyroid hormone supplements (2 Rx claims 28 or more days apart) or evidence of hyperthyroidism (2+ claims, 28 days or more apart)